Sandbox endocarditis: Difference between revisions
No edit summary |
|||
(26 intermediate revisions by the same user not shown) | |||
Line 7: | Line 7: | ||
<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #A1BCDD; text-align: center;"> | <div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #A1BCDD; text-align: center;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
'''Native Valve Endocarditis Caused by Viridans Group Streptococci and Streptococcus | '''Native Valve Endocarditis Caused by Viridans Group Streptococci and Streptococcus Bovis''' | ||
</font> | </font> | ||
</div> | </div> | ||
Line 13: | Line 13: | ||
<div class="mw-customtoggle-table11" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #4479BA;"> | <div class="mw-customtoggle-table11" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ '''Viridans Group Streptococci and Streptococcus | ▸ '''Viridans Group Streptococci and Streptococcus Bovis Highly Penicillin-Susceptible''' | ||
</font> | </font> | ||
</div> | </div> | ||
Line 19: | Line 19: | ||
<div class="mw-customtoggle-table12" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #4479BA;"> | <div class="mw-customtoggle-table12" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ '''Viridans Group Streptococci and Streptococcus | ▸ '''Viridans Group Streptococci and Streptococcus Bovis Relatively Penicillin Resistant (MIC >0.12 μg/mL- ≤ 0.5 μg/mL)''' | ||
</font> | </font> | ||
</div> | </div> | ||
Line 31: | Line 31: | ||
<div class="mw-customtoggle-table13" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #4479BA;"> | <div class="mw-customtoggle-table13" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ '''Viridans Group Streptococci and Streptococcus | ▸ '''Viridans Group Streptococci and Streptococcus Bovis Penicillin-Susceptible Strain (MIC ≤ 0.12 μg/mL)''' | ||
</font> | </font> | ||
</div> | </div> | ||
Line 37: | Line 37: | ||
<div class="mw-customtoggle-table14" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #4479BA;"> | <div class="mw-customtoggle-table14" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ '''Viridans Group Streptococci and Streptococcus | ▸ '''Viridans Group Streptococci and Streptococcus Bovis Penicillin Relatively or Fully Resistant Strain (MIC >0.12 μg/mL)''' | ||
</font> | </font> | ||
</div> | </div> | ||
Line 43: | Line 43: | ||
<div class="mw-customtoggle-table15" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #4479BA;"> | <div class="mw-customtoggle-table15" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ '''Viridans Group Streptococci and Streptococcus bovis Relatively Penicillin-Resistant Streptococci | ▸ '''Viridans Group Streptococci and Streptococcus bovis Relatively Penicillin-Resistant Streptococci (MIC 0.2–0.5 µg/ml)''' | ||
</font> | </font> | ||
</div> | </div> | ||
Line 49: | Line 49: | ||
<div class="mw-customtoggle-table16" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #4479BA;"> | <div class="mw-customtoggle-table16" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ '''Relatively Penicillin-Resistant Streptococci | ▸ '''Relatively Penicillin-Resistant Streptococci (MIC > 0.5 µg/ml)''' | ||
</font> | </font> | ||
</div> | </div> | ||
Line 62: | Line 62: | ||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table11" style="background: #FFFFFF;" | {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table11" style="background: #FFFFFF;" | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: | {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | ||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Native Valve Endocarditis Caused by Highly Penicillin-Susceptible Viridans Group Streptococci and Streptococcus bovis}} | ! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Native Valve Endocarditis Caused by Highly Penicillin-Susceptible Viridans Group Streptococci and Streptococcus bovis}} | ||
|- | |- | ||
Line 84: | Line 84: | ||
!style="padding: 0 5px; font-size: 80%; background: #F8F8FF" align=left | '''''PLUS''''' | !style="padding: 0 5px; font-size: 80%; background: #F8F8FF" align=left | '''''PLUS''''' | ||
|- | |- | ||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin| Gentamicin sulfate]] ฿ 3 mg/Kg per 24h 1 dose x 2 Wks''''' | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin| Gentamicin sulfate]] ฿ 3 mg/Kg per 24h 1 dose x 2 Wks''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}'' | ! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}'' | ||
Line 104: | Line 104: | ||
|style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left |▸'''''[[Vancomycin|Vancomycin hydrochloride]] 40 mg/kg per 24 h IV in 2–3 equally divided doses''''' | |style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left |▸'''''[[Vancomycin|Vancomycin hydrochloride]] 40 mg/kg per 24 h IV in 2–3 equally divided doses''''' | ||
|- | |- | ||
| | | | ||
Minimum inhibitory concentration ≤ 0.12 μg/mL. | |||
:† Preferred in most patients >65 y or patients with impairment of 8th cranial nerve function or renal function. | |||
:₳ Pediatric dose should not exceed that of a normal adult. | |||
< | :‡ 2-wk regimen not intended for patients with known cardiac or extracardiac abscess or for those with creatinine clearance of <20 mL/min, impaired 8th cranial nerve function, or Abiotrophia, Granulicatella, or Gemella spp infection; gentamicin dosage should be adjusted to achieve peak serum concentration of 3-4 μg/mL and trough serum concentration of >1 μg/mL when 3 divided doses are used; nomogram used for single daily dosing. | ||
:¶ Vancomycin therapy recommended only for patients unable to tolerate penicillin or ceftriaxone; vancomycin dosage should be adjusted to obtain peak (1 h after infusion completed) serum concentration of 30–45 μg/mL and a trough concentration range of 10–15 μg/mL | |||
:฿ Other potentially nephrotoxic drugs (eg, nonsteroidal antiinflammatory drugs) should be used with caution in patients receiving gentamicin therapy. Although it is preferred that gentamicin (3 mg/kg) be given as a single daily dose to adult patients with endocarditis due to viridans group streptococci, as a second option, gentamicin can be administered daily in 3 equally divided doses. | |||
|- | |- | ||
|} | |||
|} | |||
|valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table12" style="background: #FFFFFF;" | |||
| valign=top | | | valign=top | | ||
{| style=" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | ||
! style=" | ! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Native Valve Endocarditis Caused by Strains of Viridans Group Streptococci and Streptococcus Bovis Relatively Resistant to Penicillin (MIC >0.12 μg/mL- ≤ 0.5 μg/mL))}} | ||
|- | |- | ||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | !style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | ||
Line 179: | Line 154: | ||
|} | |} | ||
|} | |} | ||
|valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table13" style="background: #FFFFFF;" | |||
| valign=top | | | valign=top | | ||
{| style=" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | ||
! style=" | ! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Penicillin-susceptible strain (MIC ≤ 0.12 g/mL)}} | ||
|- | |- | ||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | !style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | ||
Line 226: | Line 190: | ||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''40 mg/kg per 24 h IV or in 2 or 3 equally divided doses''''' | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''40 mg/kg per 24 h IV or in 2 or 3 equally divided doses''''' | ||
|- | |- | ||
| | | | ||
*Dosages recommended are for patients with normal renal function. | *Dosages recommended are for patients with normal renal function. | ||
Line 234: | Line 196: | ||
:‡ Although it is preferred that gentamicin (3 mg/kg) be given as a single daily dose to adult patients with endocarditis due to viridans group streptococci, as a second option, gentamicin can be administered daily in 3 equally divided doses. | :‡ Although it is preferred that gentamicin (3 mg/kg) be given as a single daily dose to adult patients with endocarditis due to viridans group streptococci, as a second option, gentamicin can be administered daily in 3 equally divided doses. | ||
|- | |||
|} | |||
|} | |||
|valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table14" style="background: #FFFFFF;" | |||
| valign=top | | | valign=top | | ||
{| style=" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | ||
! style=" | ! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Penicillin Relatively or Fully Resistant Strain (MIC >0.12 >μg/mL)}} | ||
|- | |- | ||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | !style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | ||
Line 276: | Line 233: | ||
|} | |} | ||
|valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table15" style="background: #FFFFFF;" | |||
| valign=top | | | valign=top | | ||
{| style=" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | ||
! style=" | ! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Relatively Penicillin-Resistant Streptococci (MIC 0.2–0.5 µg/ml)}} | ||
|- | |- | ||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | !style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | ||
Line 310: | Line 259: | ||
|} | |} | ||
|} | |} | ||
|valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table16" style="background: #FFFFFF;" | |||
| valign=top | | | valign=top | | ||
{| style=" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | ||
! style=" | ! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Relatively Penicillin-Resistant Streptococci(MIC > 0.5 µg/ml, consider Enterococcal regimen)}} | ||
|- | |- | ||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | !style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | ||
Line 344: | Line 285: | ||
|} | |} | ||
|} | |} | ||
|valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table17" style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | |||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Unable to Tolerate Aqueous crystalline penicillin G sodium or Ceftriaxone}} | |||
|- | |||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''Preferred Regimen''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30 mg/kg per 24 h IV in 2 equally divided doses not to exceed 2 g/24 h, unless serum concentrations are inappropriately low ''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 40 mg/kg 24 h in 2 or 3 equally divided doses X 4 Wks ''''' | |||
|- | |||
|} | |||
|} | |||
|} | |||
==Enterococci== | |||
{| | |||
| valign=top | | |||
<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 40px; line-height: 30px; width: 250px; background: #A1BCDD; text-align: center;"> | |||
<font color="#FFF"> | |||
'''Endocarditis Caused by Enterococci''' | |||
</font> | |||
</div> | |||
<div class="mw-customtoggle-table18" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #4479BA;"> | |||
<font color="#FFF"> | |||
▸ '''Enterococci Strains Susceptible to Penicillin, Gentamicin, and Vancomycin''' | |||
</font> | |||
</div> | |||
<div class="mw-customtoggle-table19" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #4479BA;"> | |||
<font color="#FFF"> | |||
▸ '''Enterococci Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin''' | |||
</font> | |||
</div> | |||
<div class="mw-customtoggle-table20" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #4479BA;"> | |||
<font color="#FFF"> | |||
▸ '''Enterococci Strains Resistant to Penicillin and Susceptible to Aminoglycoside and Vancomycin''' | |||
</font> | |||
</div> | |||
</div></ | <div class="mw-customtoggle-table21" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #4479BA;"> | ||
<font color="#FFF"> | |||
▸ '''Enterococci Strains Resistant to Penicillin, Aminoglycoside, and Vancomycin''' | |||
</font> | |||
</div> | |||
| valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table18" style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 500px;" | |||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Enterococci Strains Susceptible to Penicillin, Gentamicin, and Vancomycin}} | |||
|- | |||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 12 g/24 h I.V.in 6 equally divided doses x 4–6 Wks'''''<br> ''OR'' <br> ▸'''''[[Penicillin G sodium]] 18–30 million U. I.V. daily in 6 equally divided doses x 4–6 Wks''''' | |||
|- | |||
|style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left |▸'''''[[Gentamicin|Gentamicin sulfate]] 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 4-6 Wks''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 300 mg/kg per 24 h IV in 4–6 equally divided doses; X 4–6 Wks''''' <br>''OR''<br> ▸'''''[[Penicillin G sodium]] 300 000 U/kg per 24 h IV in 4–6 equally divided doses X 4–6 Wks''''' | |||
|- | |||
|style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left |▸'''''[[Gentamicin|Gentamicin sulfate]] 3 mg/kg per 24 h IV/IM in 3 equally divided doses X 4-6 Wks''''' | |||
|- | |||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Alternative Regimen</u>''''' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30 mg/kg I.V. daily in 2 equally divided doses x 6 Wks'''''<br> ''PLUS'' <br> ▸'''[[Gentamicin|Gentamicin sulfate]] 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30 mg/kg I.V. daily in divided doses q. 12 hour X 4–6 Wks'''''<br> ''PLUS'' <br> ▸'''''[[Gentamicin|Gentamicin sulfate]] 3 mg/kg per 24 h IV/IM in 3 equally divided doses X 4-6 Wks''''' | |||
|- | |||
| | |||
*Native valve: 4-wk therapy recommended for patients with symptoms of illness < 3 months. | |||
*6-wk therapy recommended for patients with symptoms >3 months. | |||
*Prosthetic valve or other prosthetic cardiac material: minimum of 6 wk of therapy recommended. | |||
*Vancomycin therapy recommended only for patients unable to tolerate penicillin or ampicillin. | |||
*6 wk of vancomycin therapy recommended because of decreased activity against enterococci. | |||
|- | |||
|} | |||
|} | |||
| valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table19" style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 500px;" | |||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Enterococci Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin}} | |||
|- | |||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 12 g/24 h I.V.in 6 equally divided doses x 4–6 Wks'''''<br> ''OR'' <br> ▸'''''[[Penicillin G sodium]] 24 million U. I.V. continuously or in 6 equally divided doses x 4–6 Wks''''' | |||
|- | |||
|style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left |▸'''''[[Streptomycin|Streptomycin sulfate]] 15 mg/kg per 24 h IV/IM in 2 equally divided doses x 4-6 Wks''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 300 mg/kg per 24 h IV in 4–6 equally divided doses; x 4–6 Wks''''' <br>''OR''<br> ▸'''''[[Penicillin G sodium]] 300 000 U/kg per 24 h IV in 4–6 equally divided doses x 4–6 Wks''''' | |||
|- | |||
|style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left |▸'''''[[Streptomycin|Streptomycin sulfate]] 20–30 mg/kg per 24 h IV/IM in 2 equally divided doses''''' | |||
|- | |||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Alternative Regimen</u>''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30 mg/kg I.V. daily in 2 equally divided doses x 6 Wks'''''<br> ''PLUS'' <br> ▸'''[[Streptomycin|Streptomycin sulfate]] 15 mg/kg per 24 h IV/IM in 2 equally divided doses x 4-6 Wks''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 40 mg/kg per 24 h IV in 2 or 3 equally divided doses X 4–6 Wks'''''<br>''PLUS''<br>▸'''''[[Streptomycin|Streptomycin sulfate]] 20–30 mg/kg per 24 h IV/IM in 2 equally divided doses''''' | |||
|- | |||
| | |||
*Native valve: 4-wk therapy recommended for patients with symptoms of illness < 3 months. | |||
*6-wk therapy recommended for patients with symptoms >3 months. | |||
*Prosthetic valve or other prosthetic cardiac material: minimum of 6 wk of therapy recommended. | |||
*Vancomycin therapy recommended only for patients unable to tolerate penicillin or ampicillin. | |||
|- | |||
|} | |||
|} | |||
| valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table20" style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 500px;" | |||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|β-Lactamase–producing strain}} | |||
|- | |||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin sulbactam|Ampicillin-sulbactam]] 12 g/24 h IV in 4 equally divided doses x 6 Wks'''''<br> ''PLUS'' <br> ▸'''''[[Gentamicin|Gentamicin sulfate]] 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin sulbactam|Ampicillin-sulbactam]] 300 mg/kg per 24 h IV in 4 equally divided doses x 6 Wks''''' <br> ''PLUS'' <br> ▸'''''[[Gentamicin|Gentamicin sulfate]] 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks''''' | |||
|- | |||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Alternative Regimen</u>''''' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left |▸'''''[[Vancomycin|Vancomycin hydrochloride]] 30 mg/kg per 24 h IV in 2 equally divided doses x 6 Wks'''''<br> ''PLUS'' <br> ▸'''''[[Gentamicin|Gentamicin sulfate]] 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin|Vancomycin hydrochloride]] 40 mg/kg per 24 h in 2 or 3 equally divided doses''''' <br> ''PLUS'' <br> ▸'''''[[Gentamicin|Gentamicin sulfate]] 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks''''' | |||
|- | |||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Intrinsic penicillin resistance}} | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left |▸'''''[[Vancomycin|Vancomycin hydrochloride]] 30 mg/kg per 24 h IV in 2 equally divided doses x 6 Wks'''''<br> ''PLUS'' <br> ▸'''''[[Gentamicin|Gentamicin sulfate]] 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin|Vancomycin hydrochloride]] 40 mg/kg per 24 h in 2 or 3 equally divided doses''''' <br> ''PLUS'' <br> ▸'''''[[Gentamicin|Gentamicin sulfate]] 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks''''' | |||
|- | |||
|} | |||
|} | |||
===== | | valign=top | | ||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table21" style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 500px;" | |||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|E faecium}} | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Linezolid]] 1200 mg/24 h IV/PO in 2 equally divided doses x ≥8 Wks'''''<br> ''OR'' <br> ▸'''''[[Quinupristin dalfopristin|Quinupristin-dalfopristin]] 22.5 mg/kg per 24 h IV in 3 equally divided doses x ≥ 8 Wks''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Linezolid]] 30 mg/kg per 24 h IV/PO in 3 equally divided doses ≥8 Wks''''' <br> ''OR'' <br> ▸'''''[[Quinupristin dalfopristin|Quinupristin-dalfopristin]] 22.5 mg/kg per 24 h IV in 3 equally divided doses ≥8 Wks''''' | |||
|- | |||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF| E faecalis}}'' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult dose}}'' | |||
|- | |||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Imipenem/cilastatin]] 2 g/24 h IV in 4 equally divided doses x ≥8 Wks'''''<br> ''PLUS'' <br> ▸'''''[[Ampicillin|Ampicillin sodium]] 12 g/24 h IV in 6 equally divided doses x ≥ 8 Wks''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Imipenem/cilastatin]] 60–100 mg/kg per 24 h IV in 4 equally divided doses x ≥8 Wks'''''<br> ''PLUS'' <br> ▸'''''[[Ampicillin|Ampicillin sodium]] 300 mg/kg per 24 | |||
h IV in 4–6 equally divided doses x ≥ 8 Wks''''' | |||
|- | |||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Alternative Regimen</u>''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone|Ceftriaxone sodium]] 4 g/24 h IV/IM in 2 equally divided doses x ≥8 Wks'''''<br> ''PLUS'' <br> ▸'''''[[Ampicillin|Ampicillin sodium]] 12 g/24 h IV in 6 equally divided doses x ≥ 8 Wks''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone|Ceftriaxone sodium]] 100 mg/kg per 24 h IV/IM in 2 equally divided doses x ≥8 Wks'''''<br>''PLUS''<br> ▸'''''[[Ampicillin|Ampicillin sodium]] 300 mg/kg per 24 h IV in 4–6 equally divided doses x ≥ 8 Wks''''' | |||
|- | |||
| | |||
*Patients with endocarditis caused by these strains should be treated in consultation with an infectious diseases specialist. | |||
*Cardiac valve replacement may be necessary for bacteriologic cure. | |||
*Cure with antimicrobial therapy alone may be < 50% | |||
*Severe, usually reversible thrombocytopenia may occur with use of linezolid, especially after 2 wk of therapy. | |||
*Quinupristin-dalfopristin only effective against E faecium and can cause severe myalgias, which may require discontinuation of therapy | |||
*Only small no. of patients have reportedly been treated with imipenem/cilastatin-ampicillin or ceftriaxone + ampicillin. | |||
|- | |||
|} | |||
|} | |||
|} | |||
==Staphylococci== | |||
{| | {| | ||
| valign=top | | | valign=top | | ||
<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #A1BCDD; text-align: center;"> | |||
! style="padding: 0 5px; font-size: | <font color="#FFF"> | ||
'''Native Valve Endocarditis caused by Staphylococci in the Absence of Prosthetic Material''' | |||
</font> | |||
</div> | |||
<div class="mw-customtoggle-table23" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #4479BA;"> | |||
<font color="#FFF"> | |||
▸ '''Staphylococci (Methicillin Susceptible)''' | |||
</font> | |||
</div> | |||
<div class="mw-customtoggle-table24" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #4479BA;"> | |||
<font color="#FFF"> | |||
▸ '''Staphylococci (Methicillin-resistant) with Penicillin G Anaphylactoid Hypersensitivity ''' | |||
</font> | |||
</div> | |||
<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #A1BCDD; text-align: center;"> | |||
<font color="#FFF"> | |||
'''Prosthetic Valves Endocarditis or Other Prosthetic Material Caused by Staphylococci''' | |||
</font> | |||
</div> | |||
<div class="mw-customtoggle-table25" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #4479BA;"> | |||
<font color="#FFF"> | |||
▸ '''Oxacillin-Susceptible Strains ''' | |||
</font> | |||
</div> | |||
<div class="mw-customtoggle-table26" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #4479BA;"> | |||
<font color="#FFF"> | |||
▸ '''Oxacillin-Resistant Strains''' | |||
</font> | |||
</div> | |||
|valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table23" style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | |||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Staphylococci (Methicillin Susceptible)}} | |||
|- | |||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Nafcillin]] or [[Oxacillin]] † 12 g I.V. daily in equally divided doses x 6 Wks ''''' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | PLUS (optional) | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin|Gentamicin sulfate]] ‡ 3 mg/kg per 24 h IV/IM in 2-3 equally divided doses x 3-5 days ''''' | |||
|- | |||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Altenative Regimen</u>'''''( in non anaphylactoid [[Penicillin]] hypersensitivity) | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefazolin]] 6 g/ 24 h I.V. in 3 divided doses x 6 wks ''''' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | PLUS (optional) | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 3 mg/kg per 24 h IV/IM in 2-3 equally divided doses x 3-5 days ''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatrics dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Nafcillin]] or [[oxacillin]] 200 mg/kg per 24 h IV in 4–6 equally divided doses x 4-6 wks'''''<BR>''OR ( in non anaphylactoid [[Penicillin]] hypersensitivity)'' <BR> ▸'''''[[Cefazolin]] 100 mg/kg per 24 h IV in 3 equally divided doses x 4-6 wks''''' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | AND (optional) | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 3 mg/kg per 24 h IV/IM in 3 equally divided doses''''' | |||
|- | |||
| | |||
:† Penicillin G 24 million U/24 h IV in 4 to 6 equally divided doses may be used in place of nafcillin or oxacillin if strain is penicillin susceptible (MIC ≤ 0.1 μg/mL) and does not produce β-lactamase. | |||
:‡ Gentamicin should be administered in close temporal proximity to vancomycin, nafcillin, or oxacillin dosing. | |||
|- | |||
|} | |||
|} | |||
|valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table24" style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | |||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Staphylococci (Methicillin-resistant) <BR>(in anaphylactoid Penicillin hypersensitivity)}} | |||
|- | |- | ||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''Preferred Regimen''''' | !style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | ||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult dose}}'' | |||
|- | |||
! style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30 mg/kg per 24 h IV in 2 equally divided doses x 6 wks''''' <br> Adjust vancomycin dosage to achieve 1-h serum concentration of 30–45 > g/mL and trough concentration of 10–15 >g/mL | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatrics dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 40 mg/kg per 24 h IV in 2 or 3 equally divided doses x 6 wks ''''' | |||
|- | |||
|} | |||
|} | |||
|valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table25" style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | |||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Oxacillin-susceptible strains}} | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Nafcillin]] or [[oxacillin]] 2 g q4h IV x ≥6 weeks'''''<BR>''PLUS''<BR> ▸ '''''[[Rifampin]] 300 mg q8h IV/PO x ≥6 weeks''''' <BR>''PLUS''<BR> ▸ '''''[[Gentamicin]] 3 mg/kg per 24 h IV/IM in 2 or 3 equally divided doses x 2 weeks''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸'''''[[Nafcillin]] or [[oxacillin]] 200 mg/kg per 24 h IV in 4–6 equally divided doses'''''<BR>''PLUS''<BR> ▸'''''[[Rifampin]] 20 mg/kg per 24 h IV/PO in 3 equally divided doses'''''<BR>''PLUS''<BR>▸'''''[[Gentamicin]] 1 mg/kg q8h IV/IM''''' | |||
|- | |||
|} | |||
|} | |||
|valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table26" style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | |||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Oxacillin-resistant strains}} | |||
|- | |- | ||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult dose}}'' | ! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult dose}}'' | ||
|- | |- | ||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg q12h x ≥6 Wks'''''<BR>''PLUS''<BR> ▸ '''''[[Rifampin]] 300 mg q8h IV/PO x ≥6 Wks''''' <BR>''PLUS''<BR> ▸ '''''[[Gentamicin]] 3 mg/kg per 24 h IV/IM in 2 or 3 equally divided doses x 2 wks''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}'' | ! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}'' | ||
|- | |- | ||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 40 mg/kg 24 h in 2 | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 40 mg/kg per 24 h IV in 2-3 equally divided doses x ≥6 wks'''''<BR>''PLUS''<BR> ▸'''''[[Rifampin]] 20 mg/kg per 24 h IV/PO in 3 equally divided doses x ≥6 wks'''''<BR>''PLUS''<BR>▸ '''''[[Gentamicin]] 1 mg/kg q8h IV/IM x 2 Wks''''' | ||
|- | |- | ||
|} | |||
|} | |} | ||
|} | |} | ||
</div></div> | ==HACEK Organisms== | ||
[[HACEK organism]]s are more indolent and the infection is less complicated. | |||
<ref name="Baddour-2005">{{Cite journal | last1 = Baddour | first1 = LM. | last2 = Wilson | first2 = WR. | last3 = Bayer | first3 = AS. | last4 = Fowler | first4 = VG. | last5 = Bolger | first5 = AF. | last6 = Levison | first6 = ME. | last7 = Ferrieri | first7 = P. | last8 = Gerber | first8 = MA. | last9 = Tani | first9 = LY. | title = Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. | journal = Circulation | volume = 111 | issue = 23 | pages = e394-434 | month = Jun | year = 2005 | doi = 10.1161/CIRCULATIONAHA.105.165564 | PMID = 15956145 }}</ref> | |||
<div class="mw-collapsible-content"> | |||
{| | |||
| valign=top | | |||
<div class="mw-customtoggle-table27" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #4479BA;"> | |||
<font color="#FFF"> | |||
▸ '''Therapy for Both Native and Prosthetic Valve Endocarditis Caused by HACEK Microorganisms''' | |||
</font> | |||
</div> | |||
|valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table27" style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | |||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Therapy for Both Native and Prosthetic Valve Endocarditis Caused by HACEK Microorganisms}} | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone|Ceftriaxone sodium]] † 2 g/24 h IV/IM in 1 dose x 4 weeks''''' | |||
|- | |||
|style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ''OR'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin sulbactam|Ampicillin- sulbactam]] ‡ 12 g/24 h IV in 4 equally divided doses x 4 weeks''''' | |||
|- | |||
|style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ''OR'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ciprofloxacin]] ‡¶ 500 mg q12h PO or 400 mg q12h IV x 4 weeks''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 100 mg/kg per 24 h IV/IM once daily''''' | |||
|- | |||
|style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ''OR'' | |||
|- | |||
|style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸'''''[[Ampicillin sulbactam|Ampicillin- sulbactam]] 300 mg/kg per 24 h IV divided into 4 or 6 equally divided doses''''' | |||
|- | |||
|style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ''OR'' | |||
|- | |||
|style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸'''''[[Ciprofloxacin]] 10-15 mg/kg q12h IV/PO ''''' | |||
|- | |||
| | |||
*HACEK: Haemophilus parainfluenzae, H aphrophilus, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae. | |||
:† Patients should be informed that IM injection of ceftriaxone is painful. | |||
:‡ Dosage recommended for patients with normal renal function. | |||
:¶ Fluoroquinolones are highly active in vitro against HACEK microorganisms. Published data on use of fluoroquinolone therapy for endocarditis caused by HACEK are minimal. | |||
|- | |||
|} | |||
|} | |||
|} |
Latest revision as of 21:12, 5 March 2014
Streptococci
▸ Click on the following categories to expand treatment regimens.
Native Valve Endocarditis Caused by Viridans Group Streptococci and Streptococcus Bovis ▸ Viridans Group Streptococci and Streptococcus Bovis Highly Penicillin-Susceptible ▸ Viridans Group Streptococci and Streptococcus Bovis Relatively Penicillin Resistant (MIC >0.12 μg/mL- ≤ 0.5 μg/mL) Prosthetic Valves Endocarditis Caused by Viridans Group Streptococci and Streptococcus Bovis ▸ Viridans Group Streptococci and Streptococcus Bovis Penicillin-Susceptible Strain (MIC ≤ 0.12 μg/mL) ▸ Viridans Group Streptococci and Streptococcus Bovis Penicillin Relatively or Fully Resistant Strain (MIC >0.12 μg/mL) ▸ Viridans Group Streptococci and Streptococcus bovis Relatively Penicillin-Resistant Streptococci (MIC 0.2–0.5 µg/ml) ▸ Relatively Penicillin-Resistant Streptococci (MIC > 0.5 µg/ml) ▸ Unable to tolerate Penicillin or Ceftriaxone |
|
|
|
|
|
|
|
Enterococci
Endocarditis Caused by Enterococci ▸ Enterococci Strains Susceptible to Penicillin, Gentamicin, and Vancomycin ▸ Enterococci Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin ▸ Enterococci Strains Resistant to Penicillin and Susceptible to Aminoglycoside and Vancomycin ▸ Enterococci Strains Resistant to Penicillin, Aminoglycoside, and Vancomycin |
|
|
|
|
Staphylococci
Native Valve Endocarditis caused by Staphylococci in the Absence of Prosthetic Material ▸ Staphylococci (Methicillin Susceptible) ▸ Staphylococci (Methicillin-resistant) with Penicillin G Anaphylactoid Hypersensitivity Prosthetic Valves Endocarditis or Other Prosthetic Material Caused by Staphylococci ▸ Oxacillin-Susceptible Strains ▸ Oxacillin-Resistant Strains |
|
|
|
|
HACEK Organisms
HACEK organisms are more indolent and the infection is less complicated. [1]
▸ Therapy for Both Native and Prosthetic Valve Endocarditis Caused by HACEK Microorganisms |
|
- ↑ Baddour, LM.; Wilson, WR.; Bayer, AS.; Fowler, VG.; Bolger, AF.; Levison, ME.; Ferrieri, P.; Gerber, MA.; Tani, LY. (2005). "Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): e394–434. doi:10.1161/CIRCULATIONAHA.105.165564. PMID 15956145. Unknown parameter
|month=
ignored (help)